These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37875714)

  • 1. Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.
    Menter A
    Dermatol Ther (Heidelb); 2023 Dec; 13(12):2929-2932. PubMed ID: 37875714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.
    Menter A; Cohen S; Kay J; Strand V; Gottlieb A; Hanauer S; Eduru SK; Buschke S; Lang B; Liesenfeld KH; Schaible J; McCabe D
    Am J Clin Dermatol; 2022 Sep; 23(5):719-728. PubMed ID: 35934770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summary of Research: Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA.
    Strand V
    Rheumatol Ther; 2024 Oct; 11(5):1081-1084. PubMed ID: 39120850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study.
    Menter A; Arenberger P; Balser S; Beissert S; Cauthen A; Czeloth N; Soung J; Jazayeri S; Weisenseel P; Jayadeva G
    Expert Opin Biol Ther; 2021 Jan; 21(1):87-96. PubMed ID: 33317345
    [No Abstract]   [Full Text] [Related]  

  • 5. Adalimumab-Adbm: The First Interchangeable Biosimilar for the Treatment of Inflammatory Diseases.
    Bhat S; Patel M; Duly K; Choi D
    Ann Pharmacother; 2022 Dec; 56(12):1356-1364. PubMed ID: 35392668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plain language summary of the VOLTAIRE-RA in patients with moderate-to-severe rheumatoid arthritis.
    Cohen SB; Lee EC
    Immunotherapy; 2022 Oct; 14(15):1183-1190. PubMed ID: 36065786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity.
    Kang J; Eudy-Byrne RJ; Mondick J; Knebel W; Jayadeva G; Liesenfeld KH
    Br J Clin Pharmacol; 2020 Nov; 86(11):2274-2285. PubMed ID: 32363771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acceptability of CYLTEZO pen among biologics autoinjector patients, autoinjector Naïve patients, and healthcare professionals.
    Perez R; Suman JD; Reynolds J
    Expert Opin Drug Deliv; 2024 Aug; ():. PubMed ID: 39192830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira.
    McClellan JE; Ómarsdóttir S; Roy N; Berger V; Michel C; Berti F
    Ther Adv Chronic Dis; 2024; 15():20406223231223286. PubMed ID: 38250743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext).
    Cohen SB; Czeloth N; Lee E; Klimiuk PA; Peter N; Jayadeva G
    Expert Opin Biol Ther; 2019 Oct; 19(10):1097-1105. PubMed ID: 31387417
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA.
    Strand V; Bender S; McCabe D
    Rheumatol Ther; 2024 Oct; 11(5):1291-1302. PubMed ID: 39120847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
    Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the Interchangeability of AVT02 and Humira
    Feldman SR; Kay R; Reznichenko N; Sobierska J; Dias R; Otto H; Haliduola HN; Sattar A; Ruffieux R; Stroissnig H; Berti F
    BioDrugs; 2023 Jul; 37(4):551-567. PubMed ID: 37204631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plain language summary of the VOLTAIRE-CD study in people with moderate-to-severe active Crohn's disease.
    Hanauer S
    Immunotherapy; 2022 Dec; 14(17):1353-1359. PubMed ID: 36511191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Wins Designation as a Biosimilar Product to Humira.
    Aschenbrenner DS
    Am J Nurs; 2022 Feb; 122(2):24. PubMed ID: 35085144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects.
    Wynne C; Altendorfer M; Sonderegger I; Gheyle L; Ellis-Pegler R; Buschke S; Lang B; Assudani D; Athalye S; Czeloth N
    Expert Opin Investig Drugs; 2016 Dec; 25(12):1361-1370. PubMed ID: 27813422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar Pharmacokinetics of the Adalimumab (Humira
    Ramael S; Van Hoorick B; Tiessen R; van Iersel T; Moschetti V; Lang B; Sonderegger I; Wiebe S; Liedert B; Jayadeva G
    Rheumatol Ther; 2018 Dec; 5(2):403-421. PubMed ID: 29959660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501.
    Markus R; McBride HJ; Ramchandani M; Chow V; Liu J; Mytych D; Fanjiang G
    Adv Ther; 2019 Aug; 36(8):1833-1850. PubMed ID: 31183781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars of adalimumab: the upcoming challenge in IBD.
    Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects.
    Hyland E; Mant T; Vlachos P; Attkins N; Ullmann M; Roy S; Wagner V
    Br J Clin Pharmacol; 2016 Oct; 82(4):983-93. PubMed ID: 27285856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.